Table 1.
Baseline Characteristics
| Characteristic | Total | 20–39 | 40–49 | 50–59 | 60–69 | ≥70 |
|---|---|---|---|---|---|---|
| Number of patients | 15999 | 308 | 1615 | 4952 | 7032 | 2092 |
| Median age (range) | 62 (20–83) | 37 (20–39) | 47 (40–49) | 56 (50–59) | 65 (60–69) | 72 (70–83) |
| Gender | ||||||
| Male | 9160 (57) | 186 (60) | 908 (56) | 2841 (57) | 3960 (56) | 1265 (60) |
| Female | 6839 (43) | 122 (40) | 707 (44) | 2111 (43) | 3072 (44) | 827 (40) |
| Self-reported race | ||||||
| Caucasian | 12416 (78) | 198 (64) | 1088 (67) | 3702 (75) | 5658 (80) | 1770 (85) |
| African-American | 2683 (17) | 78 (25) | 396 (25) | 942 (19) | 1024 (15) | 243 (12) |
| Othera | 455 (3) | 18 (6) | 65 (4) | 158 (3) | 180 (3) | 34 (2) |
| Missing | 445 (3) | 14 (5) | 66 (4) | 150 (3) | 170 (2) | 45 (2) |
| Karnofsky score | ||||||
| ≥ 90 | 8562 (54) | 197 (64) | 966 (60) | 2838 (57) | 3648 (52) | 913 (44) |
| < 90 | 7263 (45) | 108 (35) | 618 (38) | 2066 (42) | 3322 (47) | 1149 (55) |
| Missing | 174 (1) | 3 (<1) | 31 (2) | 48 (<1) | 62 (<1) | 30 (1) |
| HCT-CI | ||||||
| 0 | 4276 (27) | 105 (34) | 518 (32) | 1450 (29) | 1775 (25) | 428 (20) |
| 1 | 2144 (13) | 55 (18) | 240 (15) | 663 (13) | 928 (13) | 258 (12) |
| 2 | 2831 (18) | 62 (20) | 292 (18) | 911 (18) | 1213 (17) | 353 (17) |
| 3 | 2957 (18) | 43 (14) | 292 (18) | 908 (18) | 1320 (19) | 394 (19) |
| 4 | 1711 (11) | 25 (8) | 144 (9) | 494 (10) | 775 (11) | 273 (13) |
| 5 | 980 (6) | 12 (4) | 77 (5) | 283 (6) | 449 (6) | 159 (8) |
| ≥ 6 | 1093 (7) | 6 (2) | 52 (3) | 240 (5) | 568 (8) | 227 (11) |
| Missing | 7 (<1) | 0 | 0 | 3 (<1) | 4 (<1) | 0 |
| ISS/DS stage at diagnosis | ||||||
| Stage III | 8713 (54) | 188 (61) | 949 (59) | 2697 (54) | 3811 (54) | 1068 (51) |
| Stage I-II | 6848 (43) | 117 (38) | 632 (39) | 2112 (43) | 3021 (43) | 966 (46) |
| Missing | 438 (3) | 3 (<1) | 34 (2) | 143 (3) | 200 (3) | 58 (3) |
| Cytogenetics | ||||||
| No abnormal | 3430 (21) | 73 (24) | 375 (23) | 1101 (22) | 1483 (21) | 398 (19) |
| High risk | 4398 (27) | 63 (20) | 380 (24) | 1307 (26) | 2019 (29) | 629 (30) |
| Standard risk | 4871 (30) | 98 (32) | 493 (31) | 1513 (31) | 2110 (30) | 657 (31) |
| Test not done/unknown | 3300 (21) | 74 (24) | 367 (23) | 1031 (21) | 1420 (20) | 408 (20) |
| MEL 140 | 2938 (18) | 32 (10) | 144 (9) | 475 (10) | 1064 (15) | 1223 (58) |
| MEL 200 | 13047 (82) | 276 (90) | 1468 (91) | 4473 (90) | 5962 (85) | 868 (41) |
| Unknown dose | 14 (<1) | 0 | 3 (<1) | 4 (<1) | 6 (<1) | 1 (<1) |
| Disease status prior to transplant | ||||||
| sCR/CR | 2520 (16) | 51 (17) | 269 (17) | 814 (16) | 1089 (15) | 297 (14) |
| VGPR | 6277 (39) | 117 (38) | 632 (39) | 1929 (39) | 2746 (39) | 853 (41) |
| PR | 6057 (38) | 122 (40) | 595 (37) | 1842 (37) | 2700 (38) | 798 (38) |
| SD/PD/Relapse | 1075 (7) | 18 (6) | 112 (7) | 341 (7) | 467 (7) | 137 (7) |
| Missing | 70 (<1) | 0 | 7 (<1) | 26 (<1) | 30 (<1) | 7 (<1) |
| Year of transplant | ||||||
| 2013 | 2746 (17) | 70 (23) | 327 (20) | 859 (17) | 1183 (17) | 307 (15) |
| 2014 | 2940 (18) | 60 (19) | 300 (19) | 962 (19) | 1272 (18) | 346 (17) |
| 2015 | 3034 (19) | 53 (17) | 312 (19) | 952 (19) | 1345 (19) | 372 (18) |
| 2016 | 3547 (22) | 65 (21) | 339 (21) | 1100 (22) | 1563 (22) | 480 (23) |
| 2017 | 3732 (23) | 60 (19) | 337 (21) | 1079 (22) | 1669 (24) | 587 (28) |
| Median follow-up of survivors (range), months | 25 (<1–72) | 34 (1–64) | 33 (1–71) | 27 (1–71) | 25 (1–72) | 24 (1–66) |
Legend: HCT-CI: hematopoietic cell transplant comorbidity index; ISS: International staging system; DSS: Durie-Salmon staging; VGPR: Very good partial response.